A 6-week, Randomized, Multicenter, Double-blind, Parallel, Flexed and Fixed-dose Study of MG01CI (Metadoxine Extended-release) Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome

Trial Profile

A 6-week, Randomized, Multicenter, Double-blind, Parallel, Flexed and Fixed-dose Study of MG01CI (Metadoxine Extended-release) Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2016

At a glance

  • Drugs Metadoxine (Primary)
  • Indications Fragile X syndrome
  • Focus Therapeutic Use
  • Sponsors Alcobra
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 12 Nov 2015 According to an Alcobra media release, the results from this trial will be sufficient to support a claim of efficacy for the approval of metadoxine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top